Get started
Author

Bridget C. Godwin

Observed names: B Godwin, B. Godwin, Bridget C Godwin, Bridget Godwin, Godwin B, Godwin Bridget, Godwin,Bridget, bridget godwin
OpenAlex ID: A5113031389
Persistent Basal Cell Hyperplasia Is Associated With Clinical and Endoscopic Findings in Patients With Histologically Inactive Eosinophilic Esophagitis
2019 · Kelly A. Whelan, Bridget C. Godwin, et al. · Clinical Gastroenterology and Hepatology · 81
Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use
2022 · Benjamin L. Spergel, Melanie A. Ruffner, et al. · Annals of Allergy Asthma & Immunology · 62
Autophagy mediates epithelial cytoprotection in eosinophilic oesophagitis
2016 · Kelly A Whelan, Jamie F Merves, et al. · Gut · 57
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis
2024 · Subrata Ghosh, Brian G Feagan, et al. · Journal of Crohn s and Colitis · 46
PDF
Eosinophilic esophagitis: early diagnosis is the key
2019 · Amanda B. Muir, Terri Brown-Whitehorn, et al. · Clinical and Experimental Gastroenterology · 39
PDF
EoE disease monitoring
2019 · Bridget Godwin, Benjamin Wilkins, et al. · Annals of Allergy Asthma & Immunology · 27
PDF
The Slender Esophagus: Unrecognized Esophageal Narrowing in Eosinophilic Esophagitis
2023 · Kristle L. Lynch, Alain J. Benitez, et al. · Clinical and Translational Gastroenterology · 18
A Review of Tertiary Referrals for Management of Pediatric Esophageal Eosinophilia
2018 · Bridget Godwin, Chris Liacouras, et al. · Frontiers in Pediatrics · 8
PDF
Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent
2023 · Maryia Zhdanava, Sumesh Kachroo, et al. · Clinical Therapeutics · 6
Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial
2026 · Nirmala P Gonsalves, Evan S Dellon, et al. · ˜The œLancet. Gastroenterology & hepatology · 5
Integrative Nutrition for Pediatrics
2016 · Jessi Erlichman, Amanda Hall, et al. · Current problems in pediatric and adolescent health care · 5
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease
2025 · Stefan Schreiber, Scott D Lee, et al. · Inflammatory Bowel Diseases · 3
PDF
1027 Efficacy and Safety of Intravenous Ustekinumab Reinduction Therapy in Crohn's Disease Patients With Secondary Loss of Response to Ustekinumab Maintenance Therapy: Week 16 Results From the Power Trial
2023 · Scott D. Lee, Stefan Schreiber, et al. · Gastroenterology · 3
665 Persistent Epithelial Changes in Inactive Eosinophilic Esophagitis: Is Inactive Really Inactive?
2016 · Bridget Godwin, Kelly Whelan, et al. · Gastroenterology · 3
Ustekinumab therapy for moderately to severely active pediatric Crohn’s disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg
2026 · Elisabeth De Greef, Dan Turner, et al. · Journal of Crohn s and Colitis · 2
The real-world effectiveness of ustekinumab in patients with ulcerative colitis in the United States
2025 · Sabree Burbage, Hannah Knight, et al. · Current Medical Research and Opinion · 1
Treatment Persistence Among Anti-Tumor Necrosis Factor–experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti–Tumor Necrosis Factor Agent
2024 · Maryia Zhdanava, Sabree Burbage, et al. · Clinical Therapeutics · 1
Real-world prevalence of potential drug–drug interactions associated with oral advanced therapies indicated for ulcerative colitis
2025 · Maryia Zhdanava, Sabree Burbage, et al. · Current Medical Research and Opinion
Mo2049 THE EFFECT OF USTEKINUMAB ON MUCOSAL INFLAMMATION IN PEDIATRIC CROHN'S DISEASE: THE REALITI REAL-WORLD EVIDENCE EFFECTIVENESS STUDY
2024 · Jeremy Adler, Steven J. Steiner, et al. · Gastroenterology
Mo2037 USTEKINUMAB IN DEVELOP: A SAFETY ANALYSIS FROM AN INFLAMMATORY BOWEL DISEASE MULTICENTER, PROSPECTIVE, LONG-TERM REGISTRY OF PEDIATRIC PATIENTS
2024 · Sibylle Koletzko, Gigi Veereman, et al. · Gastroenterology
Real-world Effectiveness of Ustekinumab in Patients With Ulcerative Colitis in the United States of America
2024 · Sabree Burbage, Niamh Harvey, et al. · Inflammatory Bowel Diseases
PDF
Real-world Effectiveness of Ustekinumab in Patients With Ulcerative Colitis in the United States of America.
2024 · Sabree Burbage, Niamh Harvey, et al. · Gastroenterology
PDF
P864 The Effect of Ustekinumab on Mucosal Inflammation in Paediatric Crohn’s Disease: The REALITI Real-World Evidence Effectiveness Study
2024 · J Adler, S Steiner, et al. · Journal of Crohn s and Colitis
PDF
S47 Treatment Persistence Among Anti-TNF-Experienced Patients With Ulcerative Colitis Switching to Ustekinumab or Cycling to Another Anti-TNF Agent
2023 · Maryia Zhdanava, Sabree Burbage, et al. · The American Journal of Gastroenterology
S967 Real-World Prevalence of Potential Drug-Drug Interactions Associated With Oral Advanced Therapies Indicated for Ulcerative Colitis
2023 · Maryia Zhdanava, Sabree Burbage, et al. · The American Journal of Gastroenterology
Works count: 42
Citation count: 369
H-index: 8
I10-index: 7
Year
Topic
Type